Expert Opinion on Biological Therapy, Journal Year: 2024, Volume and Issue: 24(11), P. 1245 - 1259
Published: Nov. 1, 2024
Introduction Systemic treatment options for renal cell carcinoma (RCC) have expanded considerably in recent years, and both tyrosine kinase inhibitors immune checkpoint inhibitors, alone or combination, entered the clinical arena. Adoptive immunotherapies recently revolutionized of cancer hold promise to further advance RCC.
Language: Английский
Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)
Published: Jan. 30, 2025
Abstract Recent advances in oncology research have highlighted the promising synergy between low-dose radiation therapy (LDRT) and immunotherapies, with growing evidence highlighting unique benefits of combination. LDRT has emerged as a potent tool for stimulating immune system, triggering systemic antitumor effects by remodeling tumor microenvironment. Notably, demonstrates remarkable efficacy even challenging metastatic sites such liver ( uveal ) brain cutaneous ), particularly advanced melanoma stages. The increasing interest utilizing secondary uveal, mucosal, or melanomas underscores its potential combination various immunotherapies. This comprehensive review traverses journey from laboratory to clinical applications, elucidating LDRT’s immunomodulatory role on microenvironment (TIME) responses. We meticulously examine preclinical ongoing trials, throwing light prospects complementary treatment. Furthermore, we explore challenges associated integration into therapies, addressing crucial factors optimal dosage, fractionation, treatment frequency, other pharmacological agents. Considering low toxicity profile, presents compelling case application across multiple lesions, augmenting response poly-metastatic disease scenarios. convergence disciplines holds immense developing novel radiotherapy-combined modalities, paving way more effective personalized strategies beyond. Moreover, dose-related toxicities immunotherapies may be reduced synergistic amplification LDRT.
Language: Английский
Citations
2
Experimental Hematology and Oncology, Journal Year: 2024, Volume and Issue: 13(1)
Published: Aug. 5, 2024
Abstract Chimeric antigen receptor macrophage (CAR-MΦ) represents a significant advancement in immunotherapy, especially for treating solid tumors where traditional CAR-T therapies face limitations. CAR-MΦ offers promising approach to target and eradicate tumor cells by utilizing macrophages’ phagocytic antigen-presenting abilities. However, challenges such as the complex microenvironment (TME), variability expression, immune suppression limit their efficacy. This review addresses these issues, exploring mechanisms of action, optimal construct designs, interactions within TME. It also delves into ex vivo manufacturing CAR-MΦ, discussing autologous allogeneic sources importance stringent quality control. The potential synergies integrating with existing cancer like checkpoint inhibitors conventional chemotherapeutics are examined highlight possible enhanced treatment outcomes. Furthermore, regulatory pathways scrutinized alongside established protocols cells, identifying unique considerations essential clinical trials market approval. Proposed safety monitoring frameworks aim manage adverse events, cytokine release syndrome, crucial patient safety. Consolidating current research insights, this seeks refine therapeutic applications, overcome barriers, suggest future directions transition from experimental platforms standard care options.
Language: Английский
Citations
13
Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)
Published: Aug. 8, 2024
The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 system, a groundbreaking innovation in genetic engineering, has revolutionized our approach to surmounting complex diseases, culminating CASGEVY™ approved for sickle cell anemia. Derived from microbial immune defense mechanism, CRISPR/Cas9, characterized as precision, maneuverability and universality gene editing, been harnessed versatile tool precisely manipulating DNA mammals. In the process of applying it practice, consecutive exploitation novel orthologs variants never ceases. It's conducive understanding essentialities particularly cancer, which is crucial diagnosis, prevention, treatment. CRISPR/Cas9 used not only investigate tumorous genes functioning but also model disparate cancers, providing valuable insights into tumor biology, resistance, evasion. Upon cancer therapy, instrumental developing individual precise therapies that can selectively activate or deactivate within cells, aiming cripple growth invasion sensitize cells treatments. Furthermore, facilitates development innovative treatments, enhancing targeting efficiency reprogrammed exemplified by advancements CAR-T regimen. Beyond potent screening susceptible genes, offering possibility intervening before initiative progresses. However, despite its vast potential, application research therapy accompanied significant efficacy, efficiency, technical, safety considerations. Escalating technology innovations are warranted address these issues. system revolutionizing treatment, opening up new avenues management cancers. integration this evolving clinical practice promises era precision oncology, with targeted, personalized, potentially curative patients.
Language: Английский
Citations
10
Seminars in Immunopathology, Journal Year: 2025, Volume and Issue: 47(1)
Published: Jan. 16, 2025
The management of autoimmune diseases is currently limited by therapies that largely suppress the immune system, often resulting in partial and temporary remissions. Cellular immunotherapies offer a targeted approach redirecting cells to correct underlying autoimmunity. This review explores latest advances cellular for diseases, focusing on various strategies, such as use chimeric antigen receptor (CAR) T cells, auto-antibody (CAAR) regulatory (Tregs), tolerogenic dendritic (TolDCs). We recent preclinical studies results from clinical trials demonstrate potential these either deplete autoreactive or promote tolerance through broad selective targeting cell populations. Key challenges ensuring specificity, preventing off-target effects, improving longevity therapeutic effects are discussed. evolving landscape holds promise more durable treatment responses increased specificity disease treatment.
Language: Английский
Citations
1
World Journal of Transplantation, Journal Year: 2025, Volume and Issue: 15(2)
Published: Feb. 21, 2025
Despite existing curative options like surgical removal, tissue destruction techniques, and liver transplantation for early-stage hepatocellular carcinoma (HCC), the rising incidence mortality rates of this global health burden necessitate continuous exploration novel therapeutic strategies. This review critically assesses dynamic treatment panorama HCC, focusing specifically on burgeoning role immunotherapy in two key contexts: HCC downstaging advanced to facilitate transplant candidacy. It delves into unique immunobiology highlighting tumor-mediated immune evasion mechanisms. Analyzing diverse immunotherapeutic approaches including checkpoint inhibitors, cytokine modulators, vaccines, oncolytic viruses, antigen-targeting antibodies, adoptive cell therapy, acknowledges limitations current diagnostic markers alpha-fetoprotein glypican-3 emphasizes need biomarkers patient selection monitoring. Exploring rationale neoadjuvant adjuvant research is actively exploring safety effectiveness through ongoing clinical trials. The further explores potential benefits challenges combining transplant, careful selection, meticulous monitoring, strategies mitigate post-transplant complications. Finally, latest findings from landscape future directions management, paving way optimizing improving long-term survival patients with challenging malignancy.
Language: Английский
Citations
1
Nature Biotechnology, Journal Year: 2025, Volume and Issue: 43(4), P. 516 - 533
Published: April 1, 2025
Language: Английский
Citations
1
Cancers, Journal Year: 2024, Volume and Issue: 16(12), P. 2243 - 2243
Published: June 17, 2024
Since the introduction of rituximab in late 1990s, significant progress has been made advancing targeted therapies for B cell lymphomas, improving patients’ chance being cured and clinicians’ therapeutic armamentarium. A better understanding disease biology pathogenic pathways, coupled with refinements immunophenotypic molecular diagnostics, have instrumental these achievements. While traditional chemotherapy remains fundamental most cases, concerns surrounding chemorefractoriness cumulative toxicities, particularly depletion hemopoietic reserve, underscore imperative personalized treatment approaches. Integrating agents, notably monoclonal antibodies, alongside yielded heightened response rates prolonged survival. notable paradigm shift is underway innovative-targeted replacing cytotoxic drugs, challenging conventional salvage strategies like stem transplantation. This review examines landscape emerging targets lymphoma cells explores innovative diffuse large (DLBCL). From Chimeric Antigen Receptor-T to more potent antibody–drug conjugates, bispecific checkpoint inhibitors, small molecules targeting intracellular each modality offers promising avenues advancement. aims furnish insights into their potential implications future DLBCL strategies.
Language: Английский
Citations
7
Life Sciences, Journal Year: 2024, Volume and Issue: 356, P. 123018 - 123018
Published: Aug. 28, 2024
Language: Английский
Citations
6
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: July 10, 2024
Oncolytic viruses (OVs) have emerged as a potential strategy for tumor treatment due to their ability selectively replicate in cells, induce apoptosis, and stimulate immune responses. However, the therapeutic efficacy of single OVs is limited by complexity immunosuppressive nature microenvironment (TME). To overcome these challenges, engineering has become an important research direction. This review focuses on methods multi-modal combination therapies aimed at addressing delivery barriers, viral phagocytosis, antiviral immunity therapy. The approaches discussed include enhancing vivo response, improving replication efficiency within safety profiles, targeting capabilities. In addition, this describes mechanisms combined with radiotherapy, chemotherapy, cell therapy checkpoint inhibitors (ICIs), summarizes data ongoing clinical trials. By continuously optimizing strategies programs, we can achieve improved outcomes quality life cancer patients.
Language: Английский
Citations
4
Medical Science Monitor, Journal Year: 2025, Volume and Issue: 31
Published: Jan. 15, 2025
Chimeric antigen receptor (CAR) T cells are genetically engineered lymphocytes that express a synthetic recognizes tumor cell surface antigen, which causes the lymphocyte to kill cell. As of December 2024, US Food and Drug Administration (FDA) approved six CAR T-cell therapies, with ten therapies commercially available globally, target CD19 B-cell maturation (BCMA) molecules indications include acute lymphoblastic leukemia (ALL), large lymphoma (LBCL), follicular lymphoma, mantle chronic lymphocytic (CLL), multiple myeloma. Pharmaceutical economic forecasts have shown global therapy market was worth USD 4.6 billion in projected 25 by 2035. However, there several challenges treating hematologic malignancies therapy, reduced treatment efficacy durability some patients, long-term adverse effects, lack effective salvage treatments, limited access due cost availability, rare association developing myeloid malignancies. A tumor-infiltrating (TIL) lifileucel, is FDA-approved for advanced melanoma. The (TCR) afamitresgene autoleucel, synovial sarcoma. results from ongoing studies clinical trials awaited solid tumors (melanoma, sarcomas, carcinomas). This article reviews recent developments adoptive including lymphoid organ
Language: Английский
Citations
0